Acorda Therapeutics Release: New Research Presented at 4th Collaborative Meeting of CMSC and ACTRIMS Expands Understanding of MS-Related Walking Impairment and Clinical Usage of AMPYRA®

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present research at the 4th Collaborative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) that examines the impact of walking impairment on different aspects of the lives of people with multiple sclerosis (MS), as well as the use of AMPYRA®(dalfampridine) Extended Release Tablets, 10 mg in the United States. The six company-sponsored posters will be presented on Friday, June 1 at the CMSC/ACTRIMS meeting, being held in San Diego, CA.

MORE ON THIS TOPIC